Narottam Lamichhane

Dr. Narottam Lamichhane


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
Cody BarbariCody Barbari
Cody Barbari
TFTyler Fontaine
Tyler Fontaine
PPPriyanka Parajuli
Priyanka Parajuli
NLNarottam Lamichhane
Narottam Lamichhane
SJSilvia Jakubski
Silvia Jakubski
RDRahul Deshmukh
Rahul Deshmukh
The advent of novel immunotherapies in the treatment of cancers has dramatically changed the landscape of the oncology field. Recent developments in checkpoint inhibition therapies, tumor-infiltrating lymphocyte therapies, chimeric antigen receptor T cell therapies, and cancer vaccines have shown immense promise for significant advancements in cancer treatments. Immunotherapies act on distinct steps of immune response to augment the body’s natural ability to recognize, target, and destroy cancerous cells. Combination treatments with immunotherapies and other modalities intend to activate immune response, decrease immunosuppression, and target signaling and resistance pathways to offer a more durable, long-lasting treatment compared to traditional therapies and immunotherapies as monotherapies for cancers. This review aims to briefly describe the rationale, mechanisms of action, and clinical efficacy of common immunotherapies and highlight promising combination strategies currently approved or under clinical development. Additionally, we will discuss the benefits and limitations of these immunotherapy approaches as monotherapies as well as in combination with other treatments.

5 May 2020 in Cancers
Verified
Journal Article
Open access
PDF file
PLPurushottam Lamichhane
Purushottam Lamichhane
MMMorgan Maiolini
Morgan Maiolini
OAOmar Alnafoosi
Omar Alnafoosi
SHSedra Hussein
Sedra Hussein
HAHasan Alnafoosi
Hasan Alnafoosi
RDRahul Deshmukh
Rahul Deshmukh
Colorectal cancer (CRC) is one of the most common types of cancer worldwide. There are many factors that predispose a patient to the disease such as age, family history, ethnicity, and lifestyle. There are different genetic factors and diseases that also increase a person’s risk for developing CRC. Studies have found associations between gut microbiome and the risk for developing versus protection against CRC. Normal gut microbiome aid in daily functions of the human body such as absorption, metabolism, detoxification, and regulation of inflammation. While some species of bacteria prevent CRC development and aid in therapeutic responses to various treatment regiments, other species seem to promote CRC pathogenesis. In this regard, many studies have been conducted to not only understand the biology behind these opposing different bacterial species; but also to determine if supplementation of these tumor opposing bacterial species as probiotics lends toward decreased risk of CRC development and improved therapeutic responses in patients with CRC. In this literature review, we aim to discuss the basics on colorectal cancer (epidemiology, risk factors, targets, treatments), discuss associations between different bacterial strains and CRC, and discuss probiotics and their roles in CRC prevention and treatment.

11 July 2019 in Medicines
Verified
Journal Article
Open access
PDF file
PLPurushottam Lamichhane
Purushottam Lamichhane
RDRahul Deshmukh
Rahul Deshmukh
JBJulie A Brown
Julie A Brown
SJSilvia Jakubski
Silvia Jakubski
PPPriyanka Parajuli
Priyanka Parajuli
NLNarottam Lamichhane
Narottam Lamichhane
Checkpoint inhibition (CPI) therapies have been proven to be powerful clinical tools in treating cancers. FDA approvals and ongoing clinical development of checkpoint inhibitors for treatment of various cancers highlight the immense potential of checkpoint inhibitors as anti-cancer therapeutics. The occurrence of immune-related adverse events, however, is a major hindrance to the efficacy and use of checkpoint inhibitors as systemic therapies in a wide range of patients. Hence, methods of sustained and tumor-targeted delivery of checkpoint inhibitors are likely to improve efficacy while also decreasing toxic side effects. In this review, we summarize the findings of the studies that evaluated methods of tumor-targeted delivery of checkpoint inhibitors, review their strengths and weaknesses, and discuss the outlook for therapeutic use of these delivery methods.

29 August 2024 in Nanoscale
Verified
Journal Article
Open access
PDF file
SSSai Nikhil Subraveti
Sai Nikhil Subraveti
MNMorine G. Nader
Morine G. Nader
PAPedram AziziHariri
Pedram AziziHariri
VJVijay John
Vijay John
NLNarottam Lamichhane
Narottam Lamichhane
Srinivasa RaghavanSrinivasa Raghavan
Srinivasa Raghavan
Vesicles are self-assembled nanocontainers (size ∼100 nm) in which solutes such as drugs can be encapsulated. There is great interest in triggering vesicle–micelle transitions (VMTs) because such transitions will result in the release of encapsulated solute. Here, we focus on reactive oxygen species (ROS) as a trigger for VMTs. ROS arise in our body within cells, and ROS levels are known to be high near a tumor. Thus, ROS-responsive vesicles are of interest. We make such vesicles by combining the cationic amphiphile (4-phenylthiophenyl)diphenyl-sulfonium triflate (PDST), and the anionic surfactant sodium dodecylbenzene sulfonate (SDBS). By simply mixing these two commercially available molecules in water, we prepare ‘catanionic’ vesicles in an easy, low-cost, and scalable way. When exposed to ROS such as hydrogen peroxide (H2O2), the thioether in the PDST tail gets oxidized to a hydrophilic sulfoxide. As a result, the vesicles are transformed into spherical or short, cylindrical micelles. Evidence for the VMT comes from turbidity, light scattering, and cryo-TEM measurements. The same vesicles are also sensitive to other stimuli, specifically light and temperature: i.e., a VMT can also be induced by irradiation with UV light or heating above a critical temperature. We explain the origin of the VMT in each case based on changes in the driving forces for amphiphile assembly.

4 December 2021 in Cancers
Verified
Journal Article
Open access
PDF file
PSPrerna Singh
Prerna Singh
JEJohn Gordon Eley
John Gordon Eley
NMNayab Mahmood
Nayab Mahmood
BBBinny Bhandary
Binny Bhandary
TDTijana Dukic
Tijana Dukic
HSHem Shukla
Hem Shukla
Background: Chordoma is a cancer of spinal cord, skull base, and sacral area. Currently, the standard of care to treat chordoma is resection followed by radiation therapy. Since, chordoma is present in the spinal cord and these are very sensitive structures and often complete removal by surgery is not possible. As a result, chordoma has a high chance of recurrence and developing resistance to radiation therapy. In addition, treatment of chordoma by conventional radiation therapy can also damage normal tissues surrounding chordoma. Thus, current therapeutic options to treat chordoma are insufficient and novel therapies are desperately needed to treat locally advanced and metastatic chordoma. (2) Methods: In the present investigation, human chordoma cell lines of sacral origin MUG-Chor1 and U-CH2 were cultured and irradiated with Proton Beam Radiation using the clinical superconducting cyclotron and pencil-beam (active) scanning at Middle and End of the Spread-Out Bragg Peak (SOBP). Proton radiation was given at the following doses: Mug-Chor1 at 0, 1, 2, 4, and 8 Gy and U-CH2 at 0, 4, 8, 12, and 16 Gy. These doses were selected based on a pilot study in our lab and attempted to produce approximate survival fractions in the range of 1, 0.9, 0.5, 0.1, and 0.01, respectively, chosen for linear quadratic model fitting of the dose response. (3) Results: In this study, we investigated relative biological effectiveness (RBE) of proton radiation at the end of Spread Out Bragg Peak assuming that the reference radiation is a proton radiation in the middle of the SOBP. We observed differences in the survival of both Human chordoma cell lines, U-CH2 and MUG-Chor1. The data showed that there was a significantly higher cell death at the end of the Bragg peak as compared to middle of the Bragg peak. Based on the linear quadratic (LQ) fit for cell survival we calculated the RBE between M-SOBP and E-SOBP at 95% CI level and it was observed that RBE was higher than 1 at E-SOBP and caused significantly higher cell killing. Proton field at E-SOBP caused complex DNA damage in comparison to M-EOBP and the genes such as DNA topoisomerase 1, GTSE1, RAD51B were downregulated in E-SOBP treated cells. Thus, we conclude that there seems to be substantial variation in RBE (1.3–1.7) at the E-SOBP compared with the M-SOBP.